Crestwood Equity Partners LP
CEQP News Today: Stay Updated with the Latest Crestwood Equity Partners LP News in Real Time
Find CEQP news now at Meyka AI. Stay informed with the latest Crestwood Equity Partners LP stocks updates, including price news, market analysis, and expert insights.
INR 7.00 pre-market: LONGSPUR.BO stock shows oversold bounce with 20.00% upside
Pre-market look at LONGSPUR.BO stock at INR 7.00; oversold bounce signals and a 20.00% price target
€4.001 KN.PA Natixis EURONEXT pre-market 24 Feb 2026: 36,685,840 shares most active
KN.PA stock pre-market at €4.001 on EURONEXT with heavy liquidity. Key metrics, Meyka AI grade and forecast included
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch
Pre-market: ABT.SW stock falls 13.50% to CHF86.50 on 24 Feb 2026; oversold technicals and Meyka AI projects CHF100.56 target
Pre-market 24 Feb 2026 8208.T Encho (JPX) JPY 1241.00: oversold bounce possible
Pre-market analysis of 8208.T stock at JPY 1241.00 on 24 Feb 2026 with oversold bounce setup and Meyka AI forecast
5BI.SI Polaris Ltd (SES) S$0.001 on 24 Feb 2026: Watch for oversold bounce
5BI.SI stock at S$0.001 pre-market on 24 Feb 2026; oversold bounce setup and Meyka AI forecast S$0.002
CNQ.TO Canadian Natural (TSX) C$58.02 close 23 Feb 2026: Most active, see Meyka
CNQ.TO stock closed C$58.02 on 23 Feb 2026 with 13.47M shares; technicals overbought and Meyka forecast shows downside
IDFCFIRSTB.BO stock -16.18% pre-market 24 Feb 2026: Top BSE loser, key catalyst
IDFCFIRSTB.BO stock tumbles 16.18% pre-market on BSE 24 Feb 2026. Read analysis, Meyka grade and forecast for INR 70.04
€0.08 PHR.LS Pharol, SGPS S.A. (EURONEXT) pre-market 24 Feb 2026: earnings ahead could shift valuation
PHR.LS stock trades at €0.08 pre-market on EURONEXT as investors weigh earnings and a Meyka AI forecast showing 14.11% near-term upside
UNH Stock Today: February 23 — Weak 2026 Outlook Spurs Target Cuts
UNH stock drops as 2026 revenue guidance runs about $15B below Street and Mizuho, Truist cut analyst price targets. Policy risk rises with near flat 2027 Medicare Advantage rates.